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Abstract
We examined the gene expression profiles in arthroscopic
biopsies retrieved from 10 rheumatoid arthritis patients before
and after anti-TNF treatment with infliximab to investigate
whether such profiles can be used to predict responses to the
therapy, and to study effects of the therapy on the profiles.
Responses to treatment were assessed using European League
Against Rheumatism response criteria. Three patients were
found to be good responders, five patients to be moderate
responders and two patients to be nonresponders. The TNF-α
status of the biopsies from each of the patients before treatment
was also investigated immunohistochemically, and it was
detected in biopsies from four of the patients, including all three
of the good responders. The gene expression data demonstrate
that all patients had unique gene expression signatures, with low
intrapatient variability between biopsies. The data also revealed
significant differences between the good responding and
nonresponding patients (279 differentially expressed genes
were detected, with a false discovery rate < 0.025). Among the
identified genes we found that MMP-3 was significantly
upregulated in good responders (log2  fold change, 2.95)
compared with nonresponders, providing further support for the
potential of MMP-3 as a marker for good responses to therapy.
An even more extensive list of 685 significantly differentially
expressed genes was found between patients in whom TNF-α
was found and nonresponders, indicating that TNF-α could be
an important biomarker for successful infliximab treatment.
Significant differences were also observed between biopsies
taken before and after anti-TNF treatment, including 115
differentially expressed genes in the good responding group.
Interestingly, the effect was even stronger in the group in which
TNF-α was immunohistochemically detected before therapy.
Here, 1,058 genes were differentially expressed, including many
that were novel in this context (for example, CXCL3 and
CXCL14). Subsequent Gene Ontology analysis revealed that
several 'themes' were significantly over-represented that are
known to be affected by anti-TNF treatment in inflammatory
tissue; for example, immune response (GO:0006955), cell
communication (GO:0007154), signal transduction
(GO:0007165) and chemotaxis (GO:0006935). No genes
reached statistical significance in the moderately responding or
nonresponding groups. In conclusion, this pilot study suggests
that further investigation is warranted on the usefulness of gene
expression profiling of synovial tissue to predict and monitor the
outcome of rheumatoid arthritis therapies.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
currently defined by clinical criteria [1], but knowledge is
scarce on the pathogenetic pathways involved, and the varia-
tions in this respect between different patients [2]. Since the
main inflammatory processes occur in the inflamed synovial
tissue, it is assumed that detailed analysis of molecular events
in inflamed synovia may provide additional clues regarding the
pathways involved and may identify new biomarkers for RA
[3,4]. A series of new targeted therapies have been introduced
in recent years for the treatment of RA, and several more are
anticipated [5-10]. The clinical response to currently available
therapies is quite variable between patients, and although sev-
eral of these treatments have well-defined molecular targets,
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such as TNF-α, our knowledge of the molecules and pathways
that are affected in vivo is still limited [11]. Improved knowl-
edge of individual patterns in the joints of patients and the
effects of targeted therapies would provide new opportunities
to elucidate the mode of action and to facilitate the design of
individualized treatment strategies.
Current knowledge about interindividual differences in molec-
ular patterns in inflamed RA joints originates from immunomor-
phological studies, which have shown both considerable
heterogeneity between different patients [12] and certain
striking common features, such as an abundance of macro-
phages and macrophage-derived proinflammatory cytokines in
inflamed joints of RA patients [13,14]. Few studies, however,
have presented clear evidence that immunomorphologically
recognized molecular patterns may reflect important pathoge-
netic differences between patients, or that such differences
could be used to predict responses to therapy to specific
drugs [12,15,16]. New high-throughput approaches are there-
fore needed that can analyze molecular patterns in many sam-
ples taken repeatedly during the course of a disease process,
before and after specific therapies. A highly promising
approach is microarray analysis, which allows the expression
levels of thousands of genes to be monitored simultaneously
and can therefore increase out understanding of the proc-
esses involved. Microarrays have previously been used to
investigate various aspects of RA [2,4,17-22] and its potential
uses within the field were recently reviewed by Jarvis [23].
Using a microarray approach we have previously demon-
strated that gene expression varies less between biopsies
sampled from one patient than between biopsies sampled
from different patients [24]. These findings indicated that it
would be meaningful to analyze synovial samples taken from
individuals before and after a specific treatment, and to inves-
tigate possible correlations between changes in molecular
patterns and the successfulness of the therapy. In the study
presented here we used microarrays to investigate mRNA
expression patterns in arthroscopically obtained synovial biop-
sies before and after 2 months of treatment with infliximab. Ten
patients that were treated at 0 weeks, 2 weeks and 6 weeks
were investigated. The clinical responses of the patients were
assessed using the EULAR (European League Against Rheu-
matism) response criteria [25], and synovial tissue from each
patient had previously been immunohistologically analyzed
[16] for the presence of detectable levels of TNF-α before
treatment (except for patient 10, see Materials and methods).
Real-time PCR was used to verify the transcriptional data.
Materials and methods
Patients
Ten patients (eight females and two males, median age 54
years, range 25–69 years) meeting the American College of
Rheumatology criteria for RA were recruited for the study
(Table 1). All patients received infliximab infusions of 3 mg/kg
at week 0 and again after 2 weeks and 6 weeks. Five of these
patients were receiving prednisolone in doses lower than 7.5
mg/day, and all 10 patients were treated with methotrexate to
a maximum of 20 mg/week. Patients were assessed for the
overall activity of the disease using DAS28 (disease activity
score including a 28-joint count) values before and after 12
weeks of treatment. EULAR response criteria were used to
determine the patient responses to therapy after 12 weeks of
treatment.
Synovial biopsies were obtained from all patients during
arthroscopy before and after a median of 9 weeks of treatment
(with one exception, patient 7, from whom the second biopsy
was obtained during open surgery). The biopsies obtained
were taken from the site of inflammation, which was classified
as being either close to cartilage or not close to cartilage
(defined as <1.5 cm or >1.5 cm away from cartilage, respec-
tively). All biopsies were snap-frozen in precooled isopentane
within 2 minutes to ensure high RNA quality. One biopsy was
taken before and after treatment from patients 1, 5, 7, 9 and
10, while multiple biopsies were retrieved before and/or after
treatment from patients 2, 3, 4, 6 and 8. Since only small
amounts of RNA were available for patient 9, the RNA from
this patient was only used in the second series of hybridiza-
tions (see below). The average biopsy weight was 22 mg. The
ethical committee at the Karolinska Hospital approved all
experiments on human cells and tissues. Informed consent
was obtained from all study participants.
Additional immunohistochemical data for patient 10
Synovial biopsies from patient 10 were stained and scored for
the presence of TNF-α as described by Ernestam and col-
leagues [16]. Briefly, TNF monoclonal antibodies 1 and 11
were scored using a semiquantitative four-point scale as fol-
lows: 0 = no positive cells, 1 = 1–10 positive cells, 2 = 11–
100 positive cells, and 3 => 100 positive cells. The score for
patient 10 was 1 (Table 1).
RNA extraction
RNA was successfully extracted from all biopsies essentially
as previously described [24]. Briefly, RNA was extracted from
the biopsies using steel-bead matrix tubes and a tabletop Fast-
Prep homogenizer (Qbiogene, Irvie, California, USA). After
homogenization, the tubes were centrifuged and the water
phase from each sample was collected and transferred to a
Qiashredder (Qiagen, Venlo, Netherlands) columns to ensure
complete homogenization. The RNA in the samples was puri-
fied on RNeasy spin columns (Qiagen) and was treated with
DNAse H. The extracted RNA was eluted in RNase-free water.
For further details see the KTH microarray core facility web-
page [26] ('Preparation of RNA from tissues' under 'Proto-
cols'). The average biopsy weight used for RNA extraction was
22 mg and the average RNA yield was 387 ng/μl in a volume
of 30 μl. RNA quality was assured using the RNA 6000 NanoAvailable online http://arthritis-research.com/content/8/6/R179
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LabChip kit of the Bioanalyzer system from Agilent Technolo-
gies (Santa Clara, California, USA).
RNA amplification
The extracted RNA was amplified by T7-based in vitro tran-
scription using an Arcturus (Arcturus, Mountain View, Califor-
nia, USA) RiboAmp RNA amplification kit following the
manufacturer's instructions. This procedure generates ampli-
fied RNA that consists mainly of sequences 250–1,800 bp
long. Between 300 ng and 1 μg total RNA was used in each
RNA amplification, and the average yield was 469 ng/μl in 11
μl H2O.
RNA reference
Universal Human Reference RNA from Stratagene (La Jolla,
California, USA) was used as reference RNA, amplified in the
same manner as the sample RNA. The reference RNA was
pooled before it was used for hybridization.
Labeling and cDNA synthesis
Amplified RNA was labeled as previously described [24].
Briefly, amplified RNA was labeled using random hexamer
primers in a cDNA synthesis reaction using Superscript III (Inv-
itrogen, Carlsbad, California, USA) and an amino allyl-dUTP +
dNTP mix. The mixture was incubated at 46°C for 2 hours. All
purification steps were performed using a MinElute Reaction
Cleanup Kit (Qiagen). The eluate from each sample was mixed
with a dried portion of either Cy3 or Cy5 monoreactive esters
(Amersham-Biosciences, Chalfont St Giles, UK) and was incu-
bated for 30 minutes in a dark container at room temperature.
After spin-column purification the samples were eluted and
were ready for hybridization. For further information about the
preparation of NHS-ester fluorophores and indirect labeling of
cDNA, see the KTH microarray core facility webpage [26]
(SOP 001 and SOP 002 at 'Protocols').
cDNA microarray
The cDNA arrays used in this study have been previously
described [24]. Briefly, the clones on the array (spotted
inhouse) originate from the first 310 96-well plates of a
commercial clone collection containing 46,000 sequence-ver-
ified human cDNA clones (Research Genetics, now Invitro-
gen). According to UniGene mapping performed in
September 2005, based on GenBank accession numbers
(29,717 on the whole chip), 23,300 out of the 30,000 spots
on the chip had UniGene IDs, and 13,426 of these were
unique. For more information about the chip, see the KTH
microarray core facility webpage [26].
Hybridization
The hybridization procedure has been previously described
[24]. Briefly, after prehybridization, washing and centrifuga-
tion, the two samples (one Cy5-labeled and one Cy3-labeled)
were pooled and hybridized in a water bath at 42°C for 14–18
hours. After hybridization, the slides were washed, centrifuged
dry and scanned. For further information about the hybridiza-
tion, see the KTH microarray core facility webpage [26] (SOP
003 under 'Protocols').
Table 1
Clinical data of patients
Patient Diagnosis/rheumatoid 
factor
Sex, age (years) Time of 
diagnosis
Duration of 
arthritis
DMARD Corticosteroids EULAR 
response 
criteria
TNF staining 
before 
treatmenta
1 RA, positive Female, 55 18 years NA Methotrexate 
7.5 mg/week
Prednisolone 5 
mg/day
None 0
2 RA, positive Female, 52 6 years 2 weeks Methotrexate 
17.5 mg/week
Prednisolone 5 
mg/day
Moderate 0
3 RA, positive Female, 58 2 years 6 months Methotrexate 
7.5 mg/week
Prednisolone 
7.5 mg/day
Moderate 1
4 RA, negative Female, 57 4 years 2 weeks Methotrexate 
10 mg/week
None None 0
5 RA, positive Male, 56 9 years 1 month Methotrexate 
7.5 mg/week
Prednisolone 5 
mg/day
Good 1
6 RA, negative Female, 69 1 year 1 year Methotrexate 
15 mg/week
Prednisolon 5 
mg/day
Good 1
7 RA, positive Female, 66 14 years 1 week Methotrexate 
10 mg/week
None Moderate 0
8 RA, positive Female, 66 10 years 3 weeks Methotrexate 
12.5 mg/week
None Moderate 0
9 RA, positive Male, 25 7 months 3 days Methotrexate 
17.5 mg/day
Prednisolon 20-
7.5 mg/day
Moderate 0
10 RA, positive Female, 35 26 years 1 year Methotrexate 
17.5 mg/day
Prednisolon 7.5 
mg/day
Good 1
DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; NA, not available; RA, rheumatoid arthritis.
aThe scoring system is described in Materials and methods, Additional immunohistochemical data for patient 10.Arthritis Research & Therapy    Vol 8 No 6    Lindberg et al.
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Scanning and image processing
An Agilent G2565BA scanner was used to scan the slides
and acquire 50 MB TIFF images of them. The scanner resolu-
tion was set at 10 μm. GenePix 5.1.0.0 (Axon Instruments,
Union City, California, USA) was used to extract the raw sig-
nals from the TIFF images and to assign each spot an ID.
Spots defined as 'Not Found' by GenePix were flagged with a
negative flag (-50) and were removed downstream in the anal-
ysis. Spots with a clearly abnormal morphology due to the
presence of dust particles or other factors were manually
flagged as bad (-100) and were also removed in downstream
analysis. No further processing of the slides was performed in
GenePix. The data are available at ArrayExpress, a public
repository for microarray data (accession number E-TABM-
104) [27].
Experimental design
Two series of hybridizations were performed. For each hybrid-
ization either RNA from two different samples or from one sam-
ple and reference RNA were labeled using different
fluorophores (cy3 or cy5) and were hybridized onto the same
array. Each hybridization was carried out using a dye-swapped
technical replicate, which is a replicate with the same ampli-
fied RNA but with reversed fluorophores hybridized onto a
separate array. The average correlation between the log2 fold
changes (M values) of technical replicates was 0.8. In the first
series of hybridizations, biopsies taken before treatment were
hybridized in a common reference design to enable compari-
sons between patients. In the second series of hybridizations,
biopsies taken before and after treatment were hybridized on
the same chip in a direct design. A direct design has higher
sensitivity since it provides better approximations of standard
errors in comparison with the more common reference design,
but the latter reference design allows more flexibility in down-
stream analysis [28].
Data analysis
Data were analyzed as previously described [24]. Briefly, the
data were mainly analyzed with the help of software packages
[26,29-31] available in the R language [32]. After importing
the result files (gpr files) produced by GenePix into R lan-
guage, unreliable spots with abnormal physical properties
were removed using four filters (described in [24] – more infor-
mation can be found at the KTH package webpage [26]). On
average 3,826 spots were removed by the filters, leaving
approximately 26,174 spots for downstream analysis. After fil-
tering, the slides were normalized using print-tip Loess normal-
ization [33].
A moderated t test implemented in the LIMMA (Linear Models
for Microarray Data) package [29,34] was used to identify dif-
ferentially expressed (DE) genes. The probability of falsely
identifying DE genes due to problems arising from multiple
testing was controlled using the false discovery rate approach
[35], in which a q value (analogous to a P value) is assigned
to each gene. A cutoff value was set at 0.025, which means
that the expected proportion of false positives should be less
than 0.025% among differentially expressed genes. When
making comparisons instead of merely taking the average of
replicates, the duplicateCorrelation function [36] available in
LIMMA [29] was used to acquire an approximation of gene-
wise variance. This retains valuable information about the vari-
ance when fitting a linear model to the data in order to identify
differentially expressed genes.
Biopsies were taken both close to cartilage and not close to
cartilage from patients 2, 3, 4 and 6. Data from these biopsies
were not averaged. These data were instead treated as differ-
ent biological replicates in the tests for differentially expressed
genes since these two site types are known to represent dif-
ferent cellular populations [37,38]. Functions available in Bio-
conductor [39] were used, with the help of Gene Ontology
(GO) [40] to find 'biological process' GO terms over-repre-
sented in sets of DE genes. Only GO terms represented by
more than five genes in the set of DE genes investigated were
used to reduce the amount of false positives. Each GO cate-
gory is given a P value, essentially utilizing Fisher's exact test
[41]. The P values were corrected for multiple testing using
the false discovery rate approach [35]. Several hierarchical
clusterings were performed [42], in which 1 – Pearson corre-
lation was used as the distance measure (for more detailed
information see [24]).
Real-time PCR
Up to 1 μg total RNA was used in the first-strand synthesis
reaction depending on the amount of material left, to which 2
μl 20TVN primer (4 μg/μl; Operon, Huntsville, Alabama, USA)
was added to prime the reaction. The volume was adjusted to
15.5 μl using RNase-free water, was mixed and was then incu-
bated for 10 minutes at 70°C to denature the RNA. The sam-
ples were then incubated for another 2 minutes on ice and
were spun briefly. A cDNA synthesis mixture (12.5 μl) consist-
ing of 6 μl of 5 × first-strand buffer, 3 μl of 0.1 M dithiothreitol,
2 μl Superscript III (Invitrogen) and 1.5 μl of 10 mM dNTP mix
(Amersham) were added to each sample. The whole mixture
was then incubated at 46°C for first-strand synthesis. After 1
hour the temperature was increased to 70°C for 15 minutes to
terminate the reaction. Then 2 U RNase H (Invitrogen) was
added to degrade the RNA. After RNAse treatment the tem-
perature was increased to 70°C to inactivate the RNAse. All
samples were then diluted with RNase-free water to a final vol-
ume of 200 μl.
Real-time PCR was performed using the iCycler system from
Biorad (Hercules, California, USA). Each reaction was per-
formed with 3.0 μl template, 12.5 μl iQSYBR Green Supermix
(Biorad), 300 nM primer and water to adjust the final volume
to 25 μl. The PCR amplification steps were applied in the fol-
lowing conditions: 3 minutes at 95°C, and then 40 cycles of
20 seconds at 94°C, 30 seconds at 60°C and 1 minute atAvailable online http://arthritis-research.com/content/8/6/R179
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72°C. This was followed by melt curve analysis to ensure spe-
cific amplification. The signal was calculated in all experiments
using the 'PCR base line subtracted RFU' and a cutoff value of
300 was used to establish threshold cycle values.
All primers were designed using Primer Express software (PE
Applied Biosystems, Foster City, California, USA) and ampli-
cons were designed to span exon-exon junctions to minimize
contamination by genomic DNA. Primer sequence information
is available in Additional file 1. Differences in relative expres-
sion levels between samples were calculated using the ΔΔCt
method [43] and all samples were analyzed in triplicate. β-
Actin was used as a reference gene. The following genes (with
GenBank IDs indicating the sequences present on the micro-
array) were assayed in the real-time PCR: CCL19 (GenBank
AA680186), CCL3 (GenBank AA677522), CXCL10 (Gen-
Bank AA878880), CXCL9 (GenBank AA131406), CXCL1
(GenBank W42723), CXCL3 (GenBank AA935273), IL1RN
(GenBank T72877),  FCGR1A  (GenBank AA453258),
CXCL1 (GenBank W42723), CXCL14 (GenBank AI016051)
and TNF-α (GenBank AA699697).
Results
Two series of hybridizations were performed to investigate the
differences between patients before treatment and to deter-
mine possible correlations between gene expression patterns
that could be used to predict clinical responses, and to inves-
tigate gene expression patterns before and after treatment to
identify potential molecular explanations for variations in the
clinical responses. To facilitate these two tasks we determined
and analyzed genes that were DE in different comparisons
obtained from the microarray experiments. As already
described in Materials and methods, a gene was considered
DE if q < 0.025. EULAR response criteria were used to assess
the clinical responses.
Hierarchical clustering of biopsies before treatment
Before comparing patients with differing clinical responses, a
hierarchical clustering was performed on the 876 genes that
had M values (sample versus universal RNA reference) with
interquartile ranges > 1 (Figure 1) in the first series of hybridi-
zations. This clustering was performed to obtain an overview
of the differences between the technical replicates (that is,
replicates of the same amplified RNA aliquot with reversed
fluorophores, denoted A and B), the resampled biopsies
(denoted 1 or 2) and the biological replicates in the form of dif-
ferent biopsy types (denoted close to cartilage or not close to
cartilage) from the patients. The data show that all patients had
a unique gene expression signature with low patient intravari-
ability between biopsies, in accordance with previous work
[24], but the clustering did not separate the patients clearly
into groups correlating with their EULAR responses.
Differential gene expression between different 
responder groups
To further investigate whether the differential gene expression
data retrieved from the biopsies taken before treatment corre-
lated with the clinical responses, series of comparisons were
performed between good responders (patients 5, 6 and 10),
moderate responders (patients 2, 3, 7, 8 and 9) and nonre-
sponders (patients 1 and 4). A total of 279 DE genes were
obtained when good responders were compared with
nonresponders. No genes reached statistical significance if
good responders were compared with moderate responders
and nonresponders. In contrast, 382 DE genes were statisti-
cally significant when the nonresponders were compared with
those that displayed a response (moderate or good). Twelve
genes were found to be DE between the patients in whom
TNF-α was detected before treatment immunohistochemically
(patients 3, 5, 6 and 10, hereafter denoted TNF-positive
patients) and the TNF-negative patients. Interestingly, the
highest number of DE genes (685) was found in the compari-
son of TNF-positive patients and nonresponders (Figure 2a).
These results indicate that there were similarities within the
defined responder groups and clear distinctions between the
pretreatment gene signatures of good responders and nonre-
sponders (Table 2).
Effect of treatment with infliximab
The effect of treatment with infliximab was investigated in the
second series of hybridizations, in which RNA from biopsies
Figure 1
Hierarchical cluster dendrogram of the biopsies taken before treatment Hierarchical cluster dendrogram of the biopsies taken before treatment. 
A hierarchical cluster dendrogram of the 876 genes with M values (log2 
fold change) with interquartile range > 1 in the first series of hybridiza-
tions. The clinical response of each patient is given in the plot (Euro-
pean League Against Rheumatism response criteria). pat, patient; cc, 
close to cartilage; ncc, not close to cartilage; biopsy 1 or 2 for each 
biopsy type, technical replicate A or B.Arthritis Research & Therapy    Vol 8 No 6    Lindberg et al.
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taken before and after treatment was hybridized in a direct
design. The results are presented in Figure 2b–f. These plots
display the distribution of genes obtained with different statis-
tical thresholds (y axis, negative false discovery rate on a log10
scale) in correlation to their M value (change due to treatment).
In the good responders 115 genes were DE (Figure 2b),
whereas no genes reached significance in the moderate
responders or the nonresponding patients (Figure 2c,d). A
total of 974 genes were DE (Figure 2e) when testing for the
effect of treatment using all patients, but the largest effect
(1,058 DE genes) was observed in the TNF-positive group of
patients (Figure 2f, Additional file 8).
Figure 2
Volcano plots displaying differential expression Volcano plots displaying differential expression. The y axis corresponds to the negative false discovery rate on a log10 scale. The x axis displays the 
M value (log2 fold change). Differential expression (proportion of false positives < 0.025): (a) between TNF-positive patients and nonresponders 
(685 differentially expressed (DE) genes) before treatment, (b) before and after treatment in the good responders (115 DE genes), (c) before and 
after treatment in the moderate responders (0 DE genes), (d) due to treatment in the nonresponders (no DE genes), (e) before and after treatment 
in all patients (974 DE genes), and (f) before and after treatment in the TNF-positive group of patients (1058 DE genes). TNF-α is highlighted in (e) 
and (f). FDR, false discovery rate.Available online http://arthritis-research.com/content/8/6/R179
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Over-representation analysis
To investigate whether any biological processes were over-
represented among the genes that were DE before and after
treatment in the TNF-positive patients and good responders,
GO analysis was performed as described in Materials and
methods [39]. For the TNF-positive patients (Figure 3) this
revealed significant themes related to inflammatory disease
and relevant for anti-TNF treatment, such as immune response
(GO:0006955), cell communication (GO:0007154), signal
transduction (GO:0007165) and chemotaxis (GO:0006935).
Similar themes were also significant for good responders (see
Additional files 9, 10  and 11).
Verification
Real-time PCR was performed on unamplified total RNA.
Three DE genes were verified before treatment between the
TNF-positive patients and the nonresponders. As shown in
Figure 4a, TNF-α was not DE according to results obtained
using the microarray platform. The real-time PCR results indi-
cated that TNF-α was upregulated in the patients in whom
TNF-α was detectable before treatment, but the variation was
high. The results from both approaches agreed in the direction
of changes in CXCL14 and CXCL1 levels. The change of
CXCL14 was higher according to results obtained with the
microarray platform, but this is probably due to the high varia-
tion in the real-time PCR data for this gene. Verification exper-
iments using real-time PCR were also performed on nine
genes that were DE before and after treatment in TNF-positive
patients. As displayed in Figure 4, the microarray and real-time
PCR results agreed on the expression direction (either up-reg-
ulated or downregulated) of all genes but, as shown previously
[44,45], the changes were underestimated by the microarray
relative to the real-time PCR results.
Discussion
This investigation was a pilot study of the feasibility of using
gene expression profiling to predict responses to TNF-block-
ing and to assess the effects of TNF-blocking on gene expres-
sion patterns in synovial tissues of RA patients. The results
reveal significant differences between different response
groups before treatment and identify genes that were signifi-
cantly affected by treatment in patients who responded well to
therapy and in patients where TNF could be detected immuno-
histochemically before treatment.
The first objective of this study was to investigate whether the
gene expression signatures of the arthroscopic biopsies taken
before treatment could predict the outcome of the treatment.
In the hierarchical cluster (Figure 1) based on the gene expres-
sion signature before treatment, the patients with moderate/
good EULAR responses tend to group together. A possible
explanation for the limited overall degree of separation may be
that the selection of the subset of genes chosen for clustering
was based on variations between all biopsies, instead of being
based on response groups where it was not clear a priori if the
gene expression signature related to the TNF response would
be relatively strong or weak. We therefore evaluated another
strategy – investigating genes that are differentially expressed
in groups of patients, classified on the basis of their response
to therapy according to EULAR response criteria. Clustering
of DE genes between, for example, nonresponders and good/
moderate responders resulted in a clear distinction in the den-
drogram between the two groups (see Additional file 2).
We also investigated differences in gene expression between
the groups in which TNF was present and those in which TNF
was absent in the inflamed joint tissue immunohistochemically.
The obvious assumption was that TNF-dependent pathways
can be assumed to play a more active role in the inflammation
of patients when this molecule is present in substantial
amounts prior to therapy. Previous research has suggested
that the number of TNF-α-producing cells detected immuno-
histochemically in the rheumatoid synovium may indicate the
response to infliximab therapy [12,16]. In nonresponding
patients, other molecules, and thus different pathogenic path-
ways, might be sustaining the chronic inflammation. A particu-
larly large difference in genes expressed before and after
therapy was seen in those patients who showed both TNF
expression before therapy and a good clinical response, pro-
viding indirect additional support for this hypothesis. Analysis
of differentially expressed genes before and after treatment in
all patients simultaneously resulted almost as many significant
Table 2
Results of different comparisons between responder groups using biopsies retrieved before treatment
Comparison Differentially expressed genes
Good responders versus nonresponders 279a
Good responders versus moderate responders/nonresponders 0
Nonresponders versus good responders/moderate responders 382b
TNF-positive patients versus TNF-negative patients 12a
TNF-positive patients versus nonresponders 685c
aVolcano plot and a list of the differentially expressed genes is available in Additional files 2, 3 and 4.
bVolcano plot, hierarchical cluster and a list of the differentially expressed genes is available in Additional files 2 and 5.
cA list of the differentially expressed genes and Gene Ontology analysis of the differentially expressed genes is available in Additional files 6 and 7.Arthritis Research & Therapy    Vol 8 No 6    Lindberg et al.
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genes were detected (974 DE genes) as in the TNF-positive
group, but as exemplified by TNF-α in figures 2e and 2f impor-
tant observations can be missed if confounding cohorts used
to test for a specific effect with unaffected/moderately
effected patients. Thus, even though one would be able to
detect differences due to treatment using all patients, the het-
erogeneity of the group will make it difficult to differentiate
small differences from noise (TNF-α,  q  = 0.09 using all
patients). Another obvious conclusion is that other targets
need to be identified for the treatment of nonresponders.
Several interesting GO terms were over-represented in the
genes differentially expressed before and after treatment in the
TNF-positive group (Figure 3). The genes mapped to signifi-
cant GO terms are available in Additional file 10. Previous
work has documented several mechanisms of action of TNF
antagonists in RA, the most prominent being downregulation
of synovial inflammation [12,46], reduction of cell migration
into the synovium [47], modulation of cartilage and bone
destruction markers [48-50] and induction of apoptosis [51].
It is relevant to note in this context that our GO analysis iden-
tified modulation of chemotaxis, immune functions, inflamma-
tory responses and signal transduction as potentially relevant
mechanisms. Our findings therefore confirm the relevance of
the previously described mechanisms of action for this type of
RA therapy. Moreover, these findings may facilitate the selec-
tion of better target molecules for further studies regarding the
mechanisms of action of TNF antagonists (such as the FcgRs,
Toll-like receptors and the IL18 receptor). This study might
also aid in suggesting new pathways to be studied in a more
focused approach with confirmation at the protein levels and
investigation of the clinical significance.
Figure 3
Gene Ontology analysis of the genes differentially expressed before and after treatment in the TNF-positive group of patients Gene Ontology analysis of the genes differentially expressed before and after treatment in the TNF-positive group of patients. The 20 most signifi-
cant biological processes (Gene Ontology categories) and their parent terms are shown. The color of each node illustrates significance and can be 
interpreted in the scale bar, which displays the false discovery rate on a log10 scale. The arrows indicate the parent to child direction. The numbers 
of each arrow demonstrate the amount of unique Entrez Gene IDs [57] among the DE genes that are mapped to the parent term, and the number of 
unique Entrez Gene IDs among all genes present on the chip that are mapped to the parent term.Available online http://arthritis-research.com/content/8/6/R179
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Many of the chemokines that were downregulated due to treat-
ment have previously been detected in the synovial membrane
and analyzed by immunohistochemical techniques. Some of
them are novel in this context, however; for example, CXCL3,
which was down-regulated following treatment, and CXCL14,
which had a higher level of expression in nonresponders
before treatment. The downregulation of CXCL3, a chemoat-
tractant of neutrophils, natural killer cells and cytotoxic T cells
[52], is consistent with earlier studies showing that the influx
of inflammatory cells is downregulated by TNF therapy [53].
CXCL14 has not been reported to be significant in the context
of rheumatic tissue but has been shown by Shurin and cow-
orkers [54] to be a potent chemoattractant and activator of
dendritic cells, which have been proposed to play a role in the
initiation and perpetuation of RA by presentation of arthriti-
genic antigens to autoreactive T cells [55]. CXCL1, known to
be an angiogenic protein, is particularly interesting since its
expression was higher in good responders than in nonre-
sponders before treatment, and was also found to be down-
regulated in good responders following treatment. CXCL1 has
previously been shown [56] to be induced by TNF-α and IL-1β.
In this study CXCL1 was found to be downregulated, as was
TNF-α. IL-1β was also downregulated (q value = 0.026), but
did not reach our threshold for statistical significance (q value
= 0.025).
Another interesting finding is related to the expression of
MMP-3 at the synovium level. We have previously shown that
high levels of MMP-3 in serum before treatment may indicate
good responses to therapy, as evaluated by the change in
DAS28 (disease activity score including a 28-joint count) val-
ues [48]. Our analysis of differential expression between good
and poor responders revealed an upregulation of MMP-3 in
the synovial tissue of good responders relative to nonrespond-
ers. These findings suggest that further confirmatory studies
on larger numbers of patients are warranted, with the ultimate
aim of identifying a biological marker that could be used to pre-
dict responses to treatment.
Conclusion
The present paper describes the use of an mRNA expression
array technique to analyze synovial biopsies arthroscopically
obtained before and after treatment with infliximab. Three
major results were obtained. First, we confirmed our previous
observations that intrapatient variations in biopsies are smaller
than interpatient variations, reflecting unique mRNA signa-
tures of each patient rather than tissue heterogeneity. Sec-
ondly, we demonstrated significant pretreatment differences in
gene expression between patient groups, the largest being
between the patients with positive immunohistochemical
scores for TNF-α and nonresponding patients. Thirdly, we also
observed genes differentially expressed before and after
infliximab therapy among the good responders, but the largest
differences were found when testing for effect of treatment in
the patients where TNF-α could be detected before treatment.
In summary, these results show the potential of using gene
expression profiling to elucidate the effects of anti-TNF treat-
ment in RA patients using synovial biopsies and indicate the
possibility of identifying gene expression signatures predictive
of good responses.
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